Solithromycin: Difference between revisions

Latest revision as of 10:57, 15 February 2025

Solithromycin[edit]

Solithromycin is a novel macrolide antibiotic that belongs to the ketolide class. It is designed to treat bacterial infections, particularly those caused by macrolide-resistant strains. Solithromycin is known for its broad-spectrum activity and is being investigated for its potential use in treating community-acquired bacterial pneumonia (CABP) and other infections.

Mechanism of Action[edit]

Solithromycin works by inhibiting bacterial protein synthesis. It binds to the 50S subunit of the bacterial ribosome, thereby blocking the translocation of peptides. This action is similar to other macrolides, but solithromycin has additional binding sites that enhance its activity against resistant strains.

Clinical Uses[edit]

Solithromycin is primarily being developed for the treatment of community-acquired bacterial pneumonia. It has shown effectiveness against a variety of pathogens, including:

Pharmacokinetics[edit]

Solithromycin is available in both oral and intravenous formulations. It is well absorbed when taken orally and has a long half-life, allowing for once-daily dosing. The drug is metabolized in the liver and excreted primarily in the feces.

Side Effects[edit]

Common side effects of solithromycin include:

Gastrointestinal disturbances such as nausea and diarrhea
Headache
Dizziness

Serious side effects are rare but may include liver toxicity and allergic reactions.

Development and Approval[edit]

Solithromycin was developed by Cempra Inc., and it has undergone several clinical trials to assess its safety and efficacy. As of the latest updates, it is still under review by regulatory agencies for approval in various regions.

Related Pages[edit]

@@ Line 1: / Line 1: @@
-'''Solithromycin''' is a [[macrolide]] [[antibiotic]] that is currently under development. It is a next-generation synthetic derivative of [[erythromycin]] and is designed to combat bacterial infections, including those caused by drug-resistant strains.
+== Solithromycin ==
-==Etymology==
+[[File:Solithromycin.svg|thumb|right|Chemical structure of Solithromycin]]
-The name "Solithromycin" is derived from the Latin word "solus," meaning "alone," and "thromycin," a common suffix for macrolide antibiotics. This name reflects the drug's unique mechanism of action, which allows it to work independently of other antibiotics.
-==Mechanism of Action==
+'''Solithromycin''' is a novel [[macrolide antibiotic]] that belongs to the [[ketolide]] class. It is designed to treat [[bacterial infections]], particularly those caused by [[macrolide-resistant]] strains. Solithromycin is known for its broad-spectrum activity and is being investigated for its potential use in treating [[community-acquired bacterial pneumonia]] (CABP) and other infections.
-Solithromycin works by inhibiting [[protein synthesis]] in bacteria, thereby preventing their growth and reproduction. It binds to the bacterial [[ribosome]], a cellular structure responsible for protein synthesis, and disrupts the process. This mechanism of action is similar to that of other macrolide antibiotics, but Solithromycin has been modified to overcome resistance mechanisms that have developed in bacteria against these older drugs.
-==Clinical Trials==
+== Mechanism of Action ==
-Solithromycin has undergone several phases of [[clinical trials]] to evaluate its safety and efficacy. In Phase 3 trials, it was found to be as effective as [[moxifloxacin]], a commonly used antibiotic, in treating community-acquired bacterial pneumonia. However, the drug has not yet received approval from the [[Food and Drug Administration]] (FDA) due to concerns about potential liver toxicity.
-==Related Terms==
+Solithromycin works by inhibiting bacterial [[protein synthesis]]. It binds to the 50S subunit of the bacterial [[ribosome]], thereby blocking the translocation of peptides. This action is similar to other macrolides, but solithromycin has additional binding sites that enhance its activity against resistant strains.
-* [[Macrolide]]
-* [[Antibiotic]]
+== Clinical Uses ==
-* [[Erythromycin]]
-* [[Protein synthesis]]
+Solithromycin is primarily being developed for the treatment of community-acquired bacterial pneumonia. It has shown effectiveness against a variety of pathogens, including:
-* [[Ribosome]]
-* [[Clinical trials]]
+* [[Streptococcus pneumoniae]]
-* [[Moxifloxacin]]
+* [[Haemophilus influenzae]]
-* [[Food and Drug Administration]]
+* [[Moraxella catarrhalis]]
+* [[Mycoplasma pneumoniae]]
+* [[Chlamydophila pneumoniae]]
+== Pharmacokinetics ==
+Solithromycin is available in both oral and intravenous formulations. It is well absorbed when taken orally and has a long half-life, allowing for once-daily dosing. The drug is metabolized in the liver and excreted primarily in the feces.
+== Side Effects ==
+Common side effects of solithromycin include:
+* [[Gastrointestinal disturbances]] such as nausea and diarrhea
+* [[Headache]]
+* [[Dizziness]]
+Serious side effects are rare but may include [[liver toxicity]] and [[allergic reactions]].
+== Development and Approval ==
+Solithromycin was developed by [[Cempra Inc.]], and it has undergone several clinical trials to assess its safety and efficacy. As of the latest updates, it is still under review by regulatory agencies for approval in various regions.
+== Related Pages ==
+* [[Macrolide antibiotics]]
+* [[Antibiotic resistance]]
+* [[Community-acquired pneumonia]]
 [[Category:Antibiotics]]
 [[Category:Macrolides]]
-[[Category:Drugs under development]]
+[[Category:Ketolides]]
-{{stub}}